
Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most mature data currently available of patients with primary myelofibrosis younger than 60 years. These 176 patients were followed up for a median of 8 years or until death. Improvement in survival was noted in those with high- and moderate-risk disease but not in those with low-risk disease. These findings suggest a salutary effect of recent treatment approaches, but prospective controlled trials are needed to confirm such an effect.
http://www.youtube.com/watch?v=8-v341of_kw
Cancer affects people worldwide, regardless of age, gender or socioeconomic status. That's why Mayo Clinic joins the Union for International Cancer Control and other global organizations on World Cancer ...
BARRON, Wis. — Preventive health screenings are important for everyone, yet these simple and routine things are not readily available to some. Nothing in life ...
Cancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In the last three ...